Key Highlights

  • Second-quarter net income was $80.8 million, boosted by a non-cash warrant gain.
  • Adjusted EBITDA was a loss of $11.8 million versus $9.8 million.
  • Gross revenue fell 70% to $170.1 million, with most going to crypto costs.
  • Cash and restricted cash were $50.7 million with no long-term debt.

Bakkt, Inc. (NYSE:BKKT) reported second-quarter 2026 net income attributable to the company of $80.8 million, a figure that sits alongside an adjusted EBITDA loss of $11.8 million. The gap is explained largely by a $98.5 million non-cash gain on Transchem warrants, a reminder that headline profit and underlying operating performance can diverge sharply. Investors may watch how the company's transformation into what it calls a financial operating system for the AI and token economy progresses.

Latest Company Context

Results released August 10, 2026 showed gross revenue of $170.1 million, down 70% from $568.1 million a year earlier. Crypto services revenue is reported gross, and $169.3 million of it went to crypto costs and execution, clearing and brokerage fees, so gross revenue says little about margin. Net income was $1.96 per basic share and $1.94 diluted, versus a $14.7 million loss a year earlier. Adjusted EBITDA was a loss of $11.8 million versus $9.8 million.

Operating expenses excluding crypto costs and equity compensation were $20.5 million, up 7.9%. Cash, equivalents and restricted cash were $50.7 million with no long-term debt. Bakkt acquired DTR on April 30, 2026, received 47.5 million Transchem warrants in June after Indian regulatory approvals, and raised capital through a February registered direct offering of about $48.1 million gross and $21.5 million through its at-the-market programme in the first half.

Key Business Drivers

The company operates through Bakkt Markets, Bakkt Agent and Bakkt Global. Total Transacting Volume was $168.8 million in the quarter and $410.0 million in the first half, and management expected about $2.5 billion for full-year 2026 as of the August release. Management cites Strategic Asset Value of about $118.6 million, including $107.9 million of Transchem warrants at fair value, though the company notes this is not a market or liquidation value. Because warrant valuations can swing, future quarters could see gains or losses unrelated to operations. Funding is another driver: equity raises have supported cash but may dilute existing holders.

What Investors Should Watch

Management targets initial co-branded card programmes and Neobank-as-a-Service offerings in the fourth quarter of 2026 and about 25,000 monthly active users by December 2026; these are company goals, not confirmed outcomes. The third-quarter report could show progress on transacting volume toward the full-year target, though a later-dated headline suggests that target may have been revised. Other items to watch include adjusted EBITDA losses, cash runway, further equity issuance, and any change in Transchem warrant valuation.

Accounting Profit and Operating Performance Tell Different Stories

Bakkt's latest quarter illustrates the difference between accounting profit and operating performance. A non-cash gain produced net income, while adjusted EBITDA remained negative and cash was modest. Delivery of the card, Neobank-as-a-Service and user targets is what would turn the strategy into operating results.